ES2132170T3 - Composicion de esteres de l-dopa. - Google Patents

Composicion de esteres de l-dopa.

Info

Publication number
ES2132170T3
ES2132170T3 ES93120894T ES93120894T ES2132170T3 ES 2132170 T3 ES2132170 T3 ES 2132170T3 ES 93120894 T ES93120894 T ES 93120894T ES 93120894 T ES93120894 T ES 93120894T ES 2132170 T3 ES2132170 T3 ES 2132170T3
Authority
ES
Spain
Prior art keywords
composition
active ingredient
dopa
weight
dopa esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93120894T
Other languages
English (en)
Inventor
Isaac Milman
Alexander Veinberg
Daphne Atlas
Eldad Melamed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2132170T3 publication Critical patent/ES2132170T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PRESENTA UNA COMPOSICION QUE COMPRENDE UN PORTADOR FARMACEUTICAMENTE ACEPTABLE Y UN INGREDIENTE ACTIVO, EL INGREDIENTE ACTIVO COMPRENDE UN ESTER DE ETIL DE L-DOPA EN UNA CANTIDAD QUE ES AL MENOS EL 97% DEL PESO DEL INGREDIENTE ACTIVO Y L-DOPA EN UNA CANTIDAD QUE ES MENOR DEL 1% DEL PESO DE DICHO INGREDIENTE ACTIVO. LA INVENCION SUMINISTRA ADEMAS UN PROCESO PARA PREPARAR DICHA COMPOSICION. ADEMAS, ESTA INVENCION SUMINISTRA UN METODO PARA TRATAR A UN PACIENTE QUE SUFRA DE LA ENFERMEDAD DE PARKINSON QUE COMPRENDE LA ADMINISTRACION AL PACIENTE DE UNA COMPOSICION FARMACEUTICA QUE COMPRENDA UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE ESTER DE ETIL DE L-DOPA Y UN PORTADOR FARMACOLOGICAMENTE ACEPTABLE.
ES93120894T 1992-12-24 1993-12-24 Composicion de esteres de l-dopa. Expired - Lifetime ES2132170T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA

Publications (1)

Publication Number Publication Date
ES2132170T3 true ES2132170T3 (es) 1999-08-16

Family

ID=25542272

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93120894T Expired - Lifetime ES2132170T3 (es) 1992-12-24 1993-12-24 Composicion de esteres de l-dopa.
ES98101741T Expired - Lifetime ES2150294T3 (es) 1992-12-24 1993-12-24 Composicion de esteres de l-dopa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES98101741T Expired - Lifetime ES2150294T3 (es) 1992-12-24 1993-12-24 Composicion de esteres de l-dopa.

Country Status (20)

Country Link
US (2) US5354885A (es)
EP (2) EP0867179B1 (es)
JP (1) JPH07285860A (es)
CN (1) CN1083262C (es)
AT (2) ATE178793T1 (es)
AU (1) AU684053B2 (es)
CA (1) CA2112160A1 (es)
CY (1) CY2214B1 (es)
DE (2) DE69329400T2 (es)
DK (2) DK0610595T3 (es)
ES (2) ES2132170T3 (es)
FI (1) FI107994B (es)
GR (2) GR3030073T3 (es)
HU (1) HU218906B (es)
IL (1) IL108147A (es)
LV (1) LV12766B (es)
NO (1) NO305932B1 (es)
NZ (1) NZ250541A (es)
PT (1) PT867179E (es)
ZA (1) ZA939573B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AU7669496A (en) * 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
JPH11504944A (ja) * 1995-11-06 1999-05-11 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレギリンの舌下およびバッカル投与
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
DK1063981T3 (da) * 1998-03-16 2002-10-14 Somerset Pharmaceuticals Inc Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
NZ512027A (en) * 1998-11-10 2004-04-30 Teva Pharma Dispersible compositions containing L-dopa ethyl ester
WO2000027801A1 (en) * 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Process for manufacture of l-dopa ethyl ester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
RU2173150C1 (ru) * 2000-06-27 2001-09-10 Васильев Виталий Николаевич Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
WO2003041646A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
AU2002346372A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
AU2003218307B8 (en) 2002-03-20 2006-08-31 Alkermes, Inc. Pulmonary delivery for levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
JP2006524708A (ja) * 2003-04-25 2006-11-02 インディヴァス ファーマシューティカルズ，インコーポレーテッド 塩化トロスピウムの投与により連続睡眠を促進するための方法
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
DE602004031134D1 (de) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
CA2642593C (en) * 2006-02-17 2014-11-04 Birds Pharma Gmbh Berolina Innovative Research & Development Services Deuterated catecholamine derivatives and medicaments comprising said compounds
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
PT3341380T (pt) * 2015-08-27 2019-12-19 Prexton Therapeutics Sa Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa
US20190224153A1 (en) 2016-09-29 2019-07-25 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
LT4039093T (lt) 2021-02-09 2023-11-10 Biobab R&D, S.L. 3,4-dihidroksifenilalanino (dopa) enantiomerų naudojimas ir metodas, skirtas augalų patrauklumui naudingiesiems vabzdžiams didinti

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Also Published As

Publication number Publication date
HU9303748D0 (en) 1994-04-28
CN1083262C (zh) 2002-04-24
EP0867179A1 (en) 1998-09-30
GR3030073T3 (en) 1999-07-30
EP0610595A2 (en) 1994-08-17
US5354885A (en) 1994-10-11
LV12766B (en) 2002-03-20
EP0867179B1 (en) 2000-09-06
FI107994B (fi) 2001-11-15
ATE178793T1 (de) 1999-04-15
LV12766A (lv) 2001-12-20
EP0610595A3 (en) 1994-09-21
HUT68498A (en) 1995-06-28
FI935847L (fi) 1994-06-25
ZA939573B (en) 1994-08-11
AU684053B2 (en) 1997-12-04
DE69324466T2 (de) 1999-11-25
IL108147A (en) 1998-09-24
DE69329400T2 (de) 2001-01-18
DE69324466D1 (de) 1999-05-20
GR3034867T3 (en) 2001-02-28
DK0867179T3 (da) 2000-11-06
NZ250541A (en) 1995-12-21
CN1094950A (zh) 1994-11-16
HU218906B (hu) 2000-12-28
ATE196081T1 (de) 2000-09-15
EP0610595B1 (en) 1999-04-14
ES2150294T3 (es) 2000-11-16
AU5257793A (en) 1994-07-07
DE69329400D1 (de) 2000-10-12
JPH07285860A (ja) 1995-10-31
FI935847A0 (fi) 1993-12-23
NO934768L (no) 1994-06-27
IL108147A0 (en) 1994-04-12
DK0610595T3 (da) 1999-10-25
NO305932B1 (no) 1999-08-23
US5525631A (en) 1996-06-11
NO934768D0 (no) 1993-12-22
HK1012577A1 (en) 1999-08-06
PT867179E (pt) 2000-12-29
CY2214B1 (en) 2002-11-08
CA2112160A1 (en) 1994-06-25

Similar Documents

Publication Publication Date Title
ES2132170T3 (es) Composicion de esteres de l-dopa.
NO953278D0 (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
PT92069A (pt) Processo para a producao de um sistema de distribuicao de drogas
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
NO20022264L (no) Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
MY125662A (en) Pharmaceutical formulations containing darifenacin
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
Todd et al. Transdermal Nitroglycerin (Glyceryl Trinitrate: A Review of its Pharmacology and Therapeutic Use
JPS6468320A (en) Remedy for psychotic disease or like and therapeutical solution
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
RU95110494A (ru) Средство с регулируемым высвобождением пентоксифиллина для лечения сосудистых заболеваний
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
IT1293835B1 (it) Composizioni farmaceutiche orali in forma solida a cessione modulata contenenti nicorandil e procedimento per la loro preparazione
MD1568G2 (ro) Metodă de tratament al bolii arşilor în perioada şocului combustional
MX9705820A (es) El uso de (s)-oxibutinina y (s)-desetiloxibutinina en la preparacion de composiciones para el tratamiento de incontinencia urinaria, las composiciones obtenidas y el procedimiento para preparar desetiloxibitinina.
MX9605497A (es) Composicion para tratamiento en enfermedades inflamatorias cronicas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 610595

Country of ref document: ES